ABSTRACT
INTRODUCTION
7 log 10 copies/ml, as follows : no detection of amplification signal = "Not Detected", detection 136 of amplification signal with value under 1.60 log 10 copies/ml = "Detected", absolute values 137 for quantification between 1.60 à 8.00 log 10 copies/ml, and for values above 8.00 log 10 138 copies/ml = "Upper limit of quantification". (ii) Qiagen/Artus CMV assay. with the CMV ABI Prism SDS Kit (Qiagen Hamburg GmbH, Hilde, Germany) was also 2.30 log 10 copies/ml = "Detected", absolute values for quantification between 2.30 à 8.00 152 log 10 copies/ml, and for values above 8.00 log 10 copies/ml = "Upper limit of quantification". and 50 copies/ml. The first dilution was prepared by adding 417 µl of QCMD CMV 10-08 8 fold dilution of a pool of 6 WB positive samples at 4 log 10 copies/ml in CMV negative WB.
161
For the LLQ based on QCMD and Abbott RealTime CMV expected values, each dilution was 162 tested 28 to 30 times. (ii) The between-run and within-run reproducibility was determined 163 at 3 log 10 copies/ml and 5 log 10 copies/ml by diluting serially in CMV DNA negative WB the 164 remainder of 6 CMV DNA positive WB samples with values around 6 log 10 copies/ml. Thirty 165 and eleven replicates were tested for intra-assay and inter-assay reproducibility, respectively.
166
(iii) The linearity of the assay was verified with dilutions of a highly CMV DNA positive 167 sample in CMV negative WB. These dilutions had expected viral loads ranging from 1.7 to 5 168 log 10 copies/ml. For each dilution, CMV DNA was quantified with the Abbott RealTime
169
CMV assay at least three times and the mean concentration was calculated. (95% CI) are given and were assessed using bootstrap.
on 30 replicates, were 1.37% and 2.41% at the mean values of 5.09 and 3.04 log 10 copies/ml, 211 respectively. The same two samples were tested in 11 different assays. Testing showed CV of 212 2.09% and 3.80% for 5.01 and 2.95 log 10 copies/ml, respectively. The variability of the 213 detection of the IC supplied with Abbott RealTime CMV assay to check the overall process 214 including DNA extraction and possible PCR inhibition was evaluated on the clinical samples.
215
Overall through the 302 samples tested in 14 separate experiments, no inhibition was detected (r²=0.9682) in the range of all samples tested (1.7 to 5 log 10 copies/ml) (not shown).
220
Correlation with QCMD values. CMV DNA was not detectable in the negative QCMD
221
CMV 10-05 sample and was quantified for the other 9 positive samples (Table 2) . CMV DNA 222 loads measured by the Abbott RealTime CMV assay were lower than those expected.
223
Differences between measured and expected values ranged from -0.13 (QCMD CMV 10-02) 224 to -0.55 log 10 copies/ml (QCMD CMV 10-08), with a mean of -0.26 log 10 copies/ml When 225 viral loads were expressed in copies/ml, the conversion factor between measured and 226 expected values was 1.81 (95% CI: 1.78 to 1.83).
227
Comparison of the Abbott RealTime CMV and Qiagen/Artus CMV assays. The 302 228 clinical samples were analyzed using both analytical systems. 
300
The LLQ of the assay according to the manufacturer is 40 copies/ml of WB. This threshold Qiagen/Artus CMV assays, respectively). CMV DNA loads are expressed in log 10 copies/ml. 
